Table 3. Comparison of rejection.
| n (%) | HLAi (n = 50) | ABOi (n = 65) | HLAi+ABOi (n = 5) | Control (n = 428) | LD control (n = 218) |
|---|---|---|---|---|---|
| Active ABMR | 3 (6.0) | 2 (3.1) | 0 (0.0) | 12 (2.8) | 8 (3.7) |
| Early | 2 (4.0) | 0 (0.0) | 0 (0.0) | 4 (0.9) | 3 (1.4) |
| Late | 1 (2.0) | 2 (3.1) | 0 (0.0) | 8 (1.9) | 5 (2.3) |
| Acute TCMR | 1 (2.0) | 4 (6.2) | 0 (0.0) | 25 (5.8) | 12 (5.5) |
| Early | 0 (0.0) | 2 (3.1) | 0 (0.0) | 14 (3.3) | 6 (2.8) |
| Late | 1 (2.0) | 2 (3.1) | 0 (0.0) | 11 (2.6) | 6 (2.8) |
| BPAR† | 3 (6.0) | 4 (6.2) | 0 (0.0) | 32 (7.5) | 18 (8.3) |
| Early | 2 (4.0) | 2 (3.1) | 0 (0.0) | 16 (3.7) | 8 (3.7) |
| Late | 1 (2.0) | 2 (3.1) | 0 (0.0) | 16 (3.7) | 10 (4.6) |
†There was one mixed acute TCMR and active ABMR in HLAi group, two in ABOi group, five in control group, and two in LD control group.
All P values exceeded 0.05 when compared to control and LD control group. Early indicates within 1 year and late indicates after 1 year after kidney transplantation.
Abbreviations: HLAi, HLA-incompatible; ABOi, ABO-incompatible; LD, living-donor; ABMR, antibody-mediated rejection; TCMR, T-cell mediated rejection; BPAR, biopsy-proven acute rejection.